Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age
PHASE1CompletedINTERVENTIONAL
Enrollment
8
Participants
Timeline
Start Date
December 31, 2013
Primary Completion Date
December 31, 2013
Conditions
Pharmacokinetics in Obese Adolescents
Interventions
DRUG
Lorcaserin
Trial Locations (2)
19104
Children's Hospital of Philadelphia, Philadelphia
78217
Worlwide Clinical Trials, San Antonio
All Listed Sponsors
lead
Eisai Inc.
INDUSTRY
NCT02022956 - Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age | Biotech Hunter | Biotech Hunter